公开(公告)号：US11946938B2

公开(公告)日：2024-04-02

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4745 ,  G01N2333/515 ,  G01N2800/326 ,  G01N2800/50

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20230314452A1

公开(公告)日：2023-10-05

申请号：US18021085

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G16H50/30

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210199659A1

公开(公告)日：2021-07-01

申请号：US17186163

申请日：2021-02-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Sandra Rutz ,  David Morgenstern ,  Boris Pinchuk ,  Christina Zimmermann ,  Martin Klammer ,  Franziska Sonner

IPC: G01N33/573 ,  G01N33/574

Abstract: The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

公开(公告)号：US20210181211A1

公开(公告)日：2021-06-17

申请号：US17176797

申请日：2021-02-16

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.

公开(公告)号：US20200300869A1

公开(公告)日：2020-09-24

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/68

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20190162737A1

公开(公告)日：2019-05-30

申请号：US16264779

申请日：2019-02-01

Applicant: Roche Diagnostics Operations, Inc. ,  Maastricht University Medical Center

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  Manuel Dietrich ,  Ulrich Schotten ,  Vinzent Rolny

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.

公开(公告)号：US20230366894A1

公开(公告)日：2023-11-16

申请号：US18028235

申请日：2021-09-30

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Jennifer Marie Theresia Anna Meessen ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler

IPC: G01N33/74

CPC classification number: G01N33/74 ,  G01N2333/58 ,  G01N2440/38 ,  G01N2800/326

Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

公开(公告)号：US20230305010A1

公开(公告)日：2023-09-28

申请号：US18309985

申请日：2023-05-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Anika Mang ,  David Morgenstern ,  Vinzent Rolny ,  Magdalena Swiatek-De Lange

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/8146 ,  G01N2333/96494 ,  G01N2470/04 ,  G01N2800/50 ,  G01N2800/08

Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.

公开(公告)号：US20230296630A1

公开(公告)日：2023-09-21

申请号：US18021021

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Michael Kuehne ,  Stefan Osswald

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/2814

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210239712A1

公开(公告)日：2021-08-05

申请号：US17181390

申请日：2021-02-22

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.